RobertDLegareMD

PubMed

• Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes.
  Jennifer Scalia, M Ruhul Quddus, C James Sung, Kamaljeet Singh, Robert Legare> ;Human Pathology. 2024 Apr 10
• 1 citations
  Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study.
  Mary L Lopresti, Jessica J Bian, Bachir J. Sakr, Rochelle Strenger, Robert D. Legare, Mary Anne Fenton, Sabrina M Witherby, Donald S Dizon, Sonali V Pandya, Ashley Stu...> ;Breast Cancer Research and Treatment. 2021 Jun 4
• 75 citations
  TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFOR...
  Nadine Tung, Banu Arun, Michele R. Hacker, E Hofstatter, Deborah Toppmeyer, Steven J. Isakoff, Virginia F. Borges, Robert D. Legare, Claudine Isaacs, Antonio C. Wolff,...> ;Journal of Clinical Oncology. 2020 Feb 25
• 6 citations
  Choosing high-risk screening vs. surgery and the effect of treatment modality on anxiety and breast-specific sensuality in BRCA mutation carriers.
  Kristin E. Rojas, Elizabeth Butler, Julie Gutierrez, Rebecca Kwait, Jessica Laprise, Jennifer Scalia Wilbur, Sarah Spinette, Christina Raker, Katina Robison, Robert D....> ;Gland Surgery. 2019 Jun 1
• 7 citations
  Advances in Medical Management of Early Stage and Advanced Breast Cancer: 2015
  Sabrina M Witherby, Tina Rizack, Bachir J. Sakr, Robert D. Legare, William M. Sikov> ;Seminars in Radiation Oncology. 2016 Jan 1
• 90 citations
  Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals.
  Terri Febbraro, Katina Robison, Jennifer Scalia Wilbur, Jessica Laprise, Amy Bregar, Vrishali Lopes, Robert D. Legare, Ashley Stuckey> ;Gynecologic Oncology. 2012 Mar 1
• 75 citations
  Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
  Lawrence G. Lum, Archana Thakur, Zaid Al-Kadhimi, Gerald A. Colvin, Francis J. Cummings, Robert D. Legare, Don S. Dizon, Nicola Kouttab, Abby Maizel, William Colaiace,...> ;Clinical Cancer Research. 2015 Feb 16
• 4 citations
  Is tumor board relevant
  Tina Rizack, Jennifer Gass, Robert D. Legare, Bachir J. Sakr, Don S. Dizon> ;The Breast Journal. 2013 May 1
• Genetics: predisposition and management.
  Robert D. Legare> ;Clinical Obstetrics and Gynecology. 2011 Mar 1
• 31 citations
  Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1 -associated breast cancers
  Nadine Tung, Alexander Miron, Stuart J. Schnitt, Shiva Gautam, Katharina Fetten, Jennifer Kaplan, Yosuf Yassin, Ayodele Buraimoh, Ji Young Kim, Attila Marcell Szász, R...> ;Breast Cancer Research. 2010 Nov 16
• 32 citations
  Addressing clinical trials: can the multidisciplinary Tumor Board improve participation? A study from an academic women's cancer program.
  Lindsay M. Kuroki, Ashley Stuckey, Priya Hirway, Christina Raker, Christina A. Bandera, Paul DiSilvestro, Cornelius O. Granai, Robert D. Legare, Bachir J. Sakr, Don S....> ;Gynecologic Oncology. 2010 Mar 1
• 73 citations
  Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
  Nadine Tung, Yihong Wang, Laura C. Collins, Jennifer Kaplan, Hailun Li, Rebecca Gelman, Amy Comander, Bridget Gallagher, Katharina Fetten, Karen Krag, Kathryn A. Stoec...> ;Breast Cancer Research. 2010 Feb 11
• 15 citations
  Clinical characteristics and choices regarding risk-reducing surgery in BRCA mutation carriers.
  Ashley Stuckey, Don S. Dizon, Jennifer Scalia Wilbur, Jessica Kent, Trevor Tejada-Berges, Jennifer Gass, Robert D. Legare> ;Gynecologic and Obstetric Investigation. 2010 Jan 21
• 53 citations
  Management of hematological malignancies during pregnancy.
  Tina Rizack, Anthony Mega, Robert D. Legare, Jorge J. Castillo> ;American Journal of Hematology. 2009 Dec 1
• 81 citations
  Frequent Pathologic Complete Responses in Aggressive Stages II to III Breast Cancers With Every-4-Week Carboplatin and Weekly Paclitaxel With or Without Trastuzumab: A...
  William M. Sikov, Don S. Dizon, Rochelle Strenger, Robert D. Legare, Kathy Puyana Theall, Theresa A. Graves, Jennifer Gass, Teresa Kennedy, Mary Anne Fenton> ;Journal of Clinical Oncology. 2009 Oct 1
• 9 citations
  For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
  Don S. Dizon, Antonella Restivo, Michelle Lomme, Nicole Charbonneau, Laurent Brard, Tasha Hughes, Sherry Weitzen, Robert D. Legare, Cornelius O. Granai, Paul DiSilvestro> ;American Journal of Clinical Oncology. 2008 Feb 1
• 52 citations
  Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital.
  Joanna Schwartz, Christina A. Bandera, AnnMarie Bradley, Laurent Brard, Robert D. Legare, Cornelius O. Granai, Don S. Dizon> ;Gynecologic Oncology. 2007 Apr 1
• 7 citations
  Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer.
  Don S. Dizon, Sherry Weitzen, Adam Rojan, Joanna Schwartz, Jane Miller, Paul DiSilvestro, Mary E. Gordinier, Richard G. Moore, Trevor Tejada-Berges, Leslie Pires, Robe...> ;Gynecologic Oncology. 2006 Feb 1
• 31 citations
  Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program
  Don S. Dizon, Joanna Schwartz, Adam Rojan, Jane Miller, Leslie Pires, Paul DiSilvestro, Mary E. Gordinier, Richard G. Moore, Cornelius O. Granai, Robert D. Legare> ;Gynecologic Oncology. 2006 Jan 1
• 33 citations
  PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease.
  Jan Cools, Elizabeth H Stover, Christina L Boulton, Jason Gotlib, Robert D Legare, Sonia M Amaral, David P Curley, Nicole Duclos, Rebecca Rowan, Jeffery L Kutok, Benja...> ;Cancer Cell. 2003 May 1
• 1229 citations
  A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
  Jan Cools, Daniel J. DeAngelo, Jason Gotlib, Elizabeth H. Stover, Robert D. Legare, J. E. Cortes, Jeffrey L. Kutok, Jennifer J. Clark, Ilene Galinsky, James D. Griffin...> ;The New England Journal of Medicine. 2003 Mar 27
• 1 citations
  The identification and management of hereditary breast and ovarian cancer.
  Jennifer L Scalia, Robert D Legare> ;Medicine and Health, Rhode Island. 2003 Feb 1
• 17 citations
  Risk factors for breast cancer.
  Stephen S. Falkenberry, Robert D. Legare> ;Obstetrics and Gynecology Clinics of North America. 2002 Mar 1
• 16 citations
  Adjuvant therapy in breast cancer.
  Robert D. Legare, Rochelle Strenger> ;Obstetrics and Gynecology Clinics of North America. 2002 Mar 1
• 1 citations
  The Breast Health Center at Women & Infants Hospital: origin, philosophy, and features.
  Stephen S. Falkenberry, Maureen Chung, Robert D. Legare, Rodelle Strenger, Diane Wallace, Gwen Phillips, Sara Morry, Douglas J. Marchant, Blake Cady> ;Surgical Oncology Clinics of North America. 2000 Apr 1
• Join now to see all